<DOC>
	<DOCNO>NCT00790907</DOCNO>
	<brief_summary>The purpose study compare safety two different dose regimen unfractionated heparin ( UFH ) percutaneous coronary intervention ( PCI ) procedure patient UA ( unstable angina ) /NSTEMI ( non ST segment elevation myocardial infarction ) initially treat fondaparinux .</brief_summary>
	<brief_title>Fondaparinux Trial With Unfractionated Heparin ( UFH ) During Revascularization Acute Coronary Syndromes ( ACS )</brief_title>
	<detailed_description>Subjects present hospital suspect UA NSTEMI likely undergo angiography ( ideally within 72 hour ) assess eligibility consent . Suitable subject enrol commence treatment open-label fondaparinux , 2.5 milligram ( mg ) , subcutaneous ( s.c. ) , daily . Following angiography subject indicate PCI meeting additional requirement randomization randomise receive one two dose regimen UFH either standard dose low dose immediately prior PCI procedure . Post-PCI , therapy fondaparinux ( 2.5 mg , s.c. ) may resume investigator 's discretion maximum 8 day hospital discharge , whichever early . Subjects indicate PCI , continue treatment fondaparinux , 2.5mg , s.c , daily 8 day hospital discharge , whichever early . All subject follow 30 day randomization/angiography .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>The following inclusion exclusion criterion enrollment study : Presenting admit hospital symptom suspect represent UA NSTEMI , i.e. , clinical history consistent new onset , worsen pattern , characteristic ischemic chest pain ischemic symptom occur rest minimal activity ( last longer 5 minute require sublingual nitroglycerine relief pain ) . Available enrol within 48 hour onset recent episode symptom . Planned coronary angiography , PCI indicate , within 72 hour enrollment possible . At least two three follow additional criterion : Age great equal 60 year Troponin T I CKMB upper limit normal local institution ; Electrocardiogram ( ECG ) change compatible ischemia , i.e. , ST depression least 1 mm 2 contiguous lead T wave inversion &gt; 3 mm dynamic ST shift transient ST elevation . Written inform consent date sign Age &lt; 21 year . Any contraindication UFH fondaparinux Contraindication angiography PCI baseline Subjects require urgent ( &lt; 120 minute ) coronary angiography characterize : refractory recurrent angina associate dynamic STdeviation heart failure lifethreatening arrhythmias hemodynamic instability Subjects already receive treatment enoxaparin ( LMWH ) , bivalirudin UFH treatment qualify event unless last administered ( intravenous ( i.v . ) s.c. ) dose : ≥ 8 hour low molecular weight heparin ( LMWH ) ≥60 minute bivalirudin ≥90 minute unfractionated heparin ( UFH ) Hemorrhagic stroke within last 12 month . Indication anticoagulation acute coronary syndrome ( ACS ) index hospitalization . Pregnancy woman childbearing potential use effective method contraception . Comorbid condition life expectancy le 6 month . Currently receive experimental pharmacological agent . Revascularization procedure already perform qualify event . Severe renal insufficiency ( i.e. , estimate creatinine clearance &lt; 20 ml/min ) Following angiography confirmation subject undergo PCI , subject must also meet follow additional criterion order randomise : Subjects receive least 1 dose openlabel fondaparinux The recent dose openlabel fondaparinux 24 hour start PCI procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Unstable angina</keyword>
	<keyword>Non ST elevation myocardial infarction</keyword>
	<keyword>PCI</keyword>
	<keyword>unfractionated heparin</keyword>
	<keyword>fondaparinux</keyword>
	<keyword>acute coronary syndrome</keyword>
</DOC>